What are the recommended dosing guidelines for atomoxetine in children, adolescents, and adults, including dose adjustments for CYP2D6 poor metabolizers and renal or hepatic impairment?

Atomoxetine Dosing

Atomoxetine should be initiated at 0.5 mg/kg/day in children and adolescents up to 70 kg, titrated after a minimum of 3 days to a target dose of 1.2 mg/kg/day, with a maximum of 1.4 mg/kg/day or 100 mg/day (whichever is lower); for children/adolescents over 70 kg and adults, start at 40 mg/day, increase after 3 days to 80 mg/day target, with a maximum of 100 mg/day. 1

Standard Dosing by Weight

Children and Adolescents ≤70 kg

• Initial dose: 0.5 mg/kg/day
• Target dose: 1.2 mg/kg/day (after minimum 3 days)
• Maximum dose: 1.4 mg/kg/day or 100 mg/day, whichever is lower
• After 2-4 additional weeks at target, may increase to maximum if response is suboptimal 1, 2

Children/Adolescents >70 kg and Adults

• Initial dose: 40 mg/day
• Target dose: 80 mg/day (after minimum 3 days)
• Maximum dose: 100 mg/day
• After 2-4 additional weeks at target, may increase to maximum if response is suboptimal 1

Dosing flexibility: Can be given once daily in the morning OR divided into two doses (morning and late afternoon/early evening). May be taken with or without food. 1

Critical Dose Adjustments

CYP2D6 Poor Metabolizers or Strong CYP2D6 Inhibitor Use

Approximately 7% of the population are CYP2D6 poor metabolizers with 8-10 fold higher plasma levels and significantly longer half-lives, leading to increased adverse effects 2, 3. Recent evidence shows CYP2D6 intermediate metabolizers have 1.9-fold higher exposure and poor metabolizers have 9.6-fold higher exposure compared to normal metabolizers 4.

For children/adolescents ≤70 kg:

• Initial dose: 0.5 mg/kg/day
• Target dose: 1.2 mg/kg/day ONLY if symptoms fail to improve after 4 weeks AND initial dose is well tolerated 1

For children/adolescents >70 kg and adults:

• Initial dose: 40 mg/day
• Target dose: 80 mg/day ONLY if symptoms fail to improve after 4 weeks AND initial dose is well tolerated 1

Strong CYP2D6 inhibitors requiring dose adjustment include paroxetine, fluoxetine, and quinidine 1, 2.

Hepatic Impairment

Atomoxetine clearance is significantly reduced in hepatic impairment due to decreased CYP2D6 activity and hepatic blood flow 5.

Moderate hepatic impairment (Child-Pugh Class B):

• Reduce initial and target doses to 50% of normal dose 1

Severe hepatic impairment (Child-Pugh Class C):

• Reduce initial and target doses to 25% of normal dose 1, 5

Renal Impairment

While the FDA label does not specify renal dose adjustments, emerging evidence shows end-stage renal disease can reduce hepatic CYP2D6 activity, resulting in 65% increased plasma exposure and 63% increased brain extracellular fluid levels 6. Monitor closely for adverse effects in patients with significant renal impairment and consider dose reduction if tolerability issues arise.

Pharmacogenomic Considerations

CYP2C19 polymorphisms also matter: Recent data demonstrates CYP2C192 carriers have 1.5-fold higher atomoxetine exposure regardless of CYP2D6 genotype 4. For patients who are both CYP2D6 poor/intermediate metabolizers AND CYP2C192 carriers, consider reducing the dose by an additional one-third beyond CYP2D6-based adjustments 4.

Therapeutic Drug Monitoring

Emerging evidence supports TDM-guided dosing, particularly for once-daily morning dosing:

• Therapeutic threshold: Peak plasma concentration ≥268 ng/mL associated with better response 7
• Toxicity thresholds in CYP2D6 intermediate metabolizers: CNS adverse effects at ≥465 ng/mL; GI adverse effects at ≥509 ng/mL 7

Critical Safety Monitoring

Black Box Warning: Suicidal Ideation

Monitor all children and adolescents closely for suicidality, clinical worsening, and unusual behavioral changes, especially during the first few months or at dose changes 2, 8. This risk was identified in 12 placebo-controlled trials but was not observed in adult trials 2.

Cardiovascular Monitoring

• Obtain personal and family cardiac history before initiation
• Screen for sudden death, cardiovascular symptoms, Wolff-Parkinson-White syndrome, hypertrophic cardiomyopathy, and long QT syndrome
• If risk factors present, obtain ECG and consider cardiology consultation 8
• Monitor blood pressure and heart rate at baseline and during treatment 8

Other Monitoring

• Screen for bipolar disorder before initiating treatment 8, 1
• Monitor for emergence of psychotic/manic symptoms, aggressive behavior, or hostility 2, 8
• Monitor height and weight in pediatric patients (growth delays may occur in first 1-2 years) 8
• Discontinue if jaundice or laboratory evidence of liver injury develops 8

Maintenance Treatment

The benefit of long-term atomoxetine treatment (dose range 1.2-1.8 mg/kg/day) has been demonstrated in controlled trials 1. Periodically reassess the need for continued treatment. Atomoxetine can be discontinued without tapering 1.

Common Pitfalls to Avoid

1. Do not increase dose too rapidly - wait minimum 3 days before initial titration, then 2-4 weeks before further increases
2. Do not ignore CYP2D6 status - failure to adjust dosing in poor metabolizers or with strong inhibitors dramatically increases adverse effect risk
3. Do not use with MAOIs - contraindicated within 2 weeks of MAOI use 1
4. Do not use in narrow-angle glaucoma, pheochromocytoma, or severe cardiovascular disorders 1
5. Do not open capsules - must be swallowed whole 1